New enzyme may shorten hospital stays for bone cancer patients on chemo

NCT ID NCT03960177

Ongoing Symptom relief Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 27 times

Summary

This early study tests whether a drug called glucarpidase can lower the toxic side effects of high-dose methotrexate in adults with osteosarcoma (a type of bone cancer). About 12 participants will receive glucarpidase alongside their chemotherapy to see if it helps clear the chemo drug faster, potentially leading to shorter hospital stays and fewer complications. The goal is to make treatment safer and more tolerable, not to cure the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
OHSU Knight Cancer Institute

Portland, Oregon, 97239, United States
University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.

OSTEOSARCOMA